PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
38.10%
Revenue growth above 1.5x 5715.T's 9.27%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-1.49%
Negative gross profit growth while 5715.T is at 0.39%. Joel Greenblatt would examine cost competitiveness or demand decline.
-38.17%
Negative EBIT growth while 5715.T is at 110.76%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.64%
Negative operating income growth while 5715.T is at 11.31%. Joel Greenblatt would press for urgent turnaround measures.
-27.98%
Negative net income growth while 5715.T stands at 63.90%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-28.02%
Negative EPS growth while 5715.T is at 63.89%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-28.02%
Negative diluted EPS growth while 5715.T is at 63.89%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.38%
OCF growth above 1.5x 5715.T's 0.87%. David Dodd would confirm a clear edge in underlying cash generation.
14.38%
FCF growth above 1.5x 5715.T's 0.87%. David Dodd would verify if the firm’s strategic investments yield superior returns.
67.46%
10Y revenue/share CAGR above 1.5x 5715.T's 44.84%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-49.63%
Negative 5Y CAGR while 5715.T stands at 34.32%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-22.53%
Negative 3Y CAGR while 5715.T stands at 37.25%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.05%
Negative 10Y net income/share CAGR while 5715.T is at 47.44%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-84.89%
Negative 5Y net income/share CAGR while 5715.T is 269.68%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-74.03%
Negative 3Y CAGR while 5715.T is 19716.91%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
107.45%
10Y equity/share CAGR in line with 5715.T's 117.59%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
29.24%
5Y equity/share CAGR is in line with 5715.T's 28.35%. Walter Schloss would see parallel mid-term profitability and retention policies.
21.55%
3Y equity/share CAGR at 50-75% of 5715.T's 40.21%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.74%
Firm’s AR is declining while 5715.T shows 15.66%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-21.30%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-7.12%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.72%
Similar to 5715.T's 1.59%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-11.27%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-11.76%
Our R&D shrinks while 5715.T invests at 28.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
9.10%
We expand SG&A while 5715.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.